Skip to main content
. 2021 Oct 6;12:749365. doi: 10.3389/fphar.2021.749365

FIGURE 1.

FIGURE 1

The MOPr/DOPr agonist LP2 shows an anti-allodynic effect in CCI animal model. (A) Schematic representation of the experimental design. WB = Western Blot; Real Time-PCR = Real Time Polymerase Chain Reaction; IHF = Immunohistofluorescence analysis. (B) Withdrawal thresholds measured with von Frey’s filaments on SHAM-vehicle, on SHAM-vehicle, CCI-vehicle, and CCI + LP2-treated rats at 0, 11 (before the start of LP2 administration), 16, and 21 dpl. Data are shown as mean ± SEM of n = 8 rats per group. *p < 0.001 vs SHAM-vehicle. # p < 0.001 vs. CCI-vehicle.